TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Observed Concentration (Cmax) of UPB-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Concentration (Tmax) of UPB-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC From Time Zero up to the Last Quantifiable Concentration of UPB-101 (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral center of mass (COM) excursion during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes improving ≥2 steps on the ETDRS DRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Knowledge and self-efficacy regarding drug testing for fentanyl
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opioid overdose rate
Endpoint domain: Mortality/survival
Primary endpoint: Cmin (minimum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional composition analysis (macro and micronutrients)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inclination Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anteversion Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Cognitive Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in ctDNA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve (AUC) From Time 0 to 21 Days (AUC21d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC at Steady State Between Week 16 and Week 19 (AUCtau_ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee Score (IKDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tegner-Lysholm Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Carbohydrate Oxidation during Steady-state Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of other events of interest
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate specific antigen (PSA)50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in volumetric olfactory cleft opacification based on CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in olfactory cleft endoscopy score based on nasalendoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in overall polyp score from sinonasal endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oxygen Dissociation Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological Symptoms of Anxiety Follow-up Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-versus-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-versus-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum (peak) drug concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of IgG antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect on MEN1-associated tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lung ultrasound scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in surgical ergonomic knowledge score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in surgical ergonomic practice based on rapid upper limb assessment (RULA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in surgical ergonomic practice based on rapid entire body assessment (REBA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis severity symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HA Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Screening completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pelvic Pain Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Female Sexual Function Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Female Sexual Distress Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaginal Penetration Cognition Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arterial pCO2 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Consenting AYA use AYA-RISE
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number/extent of lesions with at least a moderate uptake of RLI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage changes in quantitative PET parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration to achieve target MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3 or higher serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Good neurologic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean change in symptom bother
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in LBTC rates
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention Appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Intervention Treatment Receipt
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CR Rate (cohort 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-month DFS Rate (cohort 1、3、4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Auditory Verbal Learning Test-HuaShan version (AVLT-H)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digital Symbol Coding (DSC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal Fluency Test (VFT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clock Drawing Task (CDT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with solicited local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting all adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with medically important adverse events, adverse events of special interest, serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in low-density lipoprotein (LDL)-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Partial pressure of carbon dioxide at the nasal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxford Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Tumor Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microbiologic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th17 cytokines concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ways of Coping with Stress Inventory (WCI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: The subjective units of distress scale (SUD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Two-year prognosis in patients with cardiac amyloidosis
Endpoint domain: Mortality/survival
Primary endpoint: Change in total NIH-CPSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of Early Enamel Caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Laser Fluorescence Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Perspectives on Tooth Colour Changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in appetite-related hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent of participants who purchase product
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of pain when mobilising from supine to sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal and neonatal serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival (percentage of participants alive)
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (percentage of participants with no evidence of further disease progression)
Endpoint domain: Mortality/survival
Primary endpoint: Time to first biopsy-confirmed keratinocyte carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: The proportion of Fusobacterium nucleatum and Porphyromonas gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of MRI techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Clinical Data Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Polygenic Risk Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with accurate Imaging Radiomics and Composite Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Multiparametric and ML Analyse outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usefulness by parent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in cancer-related cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline values of diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: transpulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion Regulation Ability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotion Regulation Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Equivalence between aRECIST and manual RECIST in the evaluation of target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of imaging biomarkers that discriminate EGFR status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Unsolicited study product related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serious AEs, AEs of Special Interest, Medically Attended AEs, and New-Onset of Chronic Diseases
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of travel-related infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of the Vent2Cool procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the SARA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the 9-Hole Peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the 8 meters walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in the PATA rate test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Barthel index for Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in SF36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge of negative consequences of smoking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Autonomic dysfunction severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing time required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk rejection as measured by a numeric estimate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk rejection as measured by risk relative to a typical woman their age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk rejection as measured by a validated believability scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety levels measured by the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of mental imagery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vividness of mental imagery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of emotions related to mental imagery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to antiplatelet drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to statin therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gut Microbiome diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with New-onset-DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with death
Endpoint domain: Mortality/survival
Primary endpoint: Change in midline shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of major pathological response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving hemoglobin levels ≥ 12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of aneurysms with complete occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Score in Upper arm function and advanced hand activities sections of Motor Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score in Motricity index (Arm section)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score in Barthel index for activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oxygen Wean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of parent-infant dyads enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Root mean squared error (RMSE) of predictions for manifest astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average intraoperative urethral perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-week transplant-free mortality
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of neurological complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of Erectile Dysfunction (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Proviral HIV DNA quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Episomal Proviral HIV DNA quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apoptosis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of days post-operative till passing stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knee Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Antitumor efficacy of XNW28012
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bioelectrical Retinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of specific intraoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to complete the procedure as planned
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of emergency room admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in the inflammatory marker IL-6 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Growth of perihematomal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neurological worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GMI of neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: spirometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of ethinyl estradiol/levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration (tmax) of ethinyl estradiol/levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-Time Curve (AUC 0-t) of ethinyl estradiol/levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of distinct Bifidobacterium species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentrations (Cmax) for IBI351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentrations (Cmax) for dextromethorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve from time 0 to infinity (AUC0-inf) for IBI351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve from time 0 to infinity (AUC0-inf) for dextromethorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extension and flexion isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of direction sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of first aiders per hour
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grams of pizza consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline medial prefrontal cortex oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline lateral prefrontal cortex oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GLP-1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PYY response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CCK response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ghrelin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes